Cargando…
Changes in m6A in Steatotic Liver Disease
Fatty liver disease is one of the major causes of morbidity and mortality worldwide. Fatty liver includes non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), now replaced by a consensus group as metabolic dysfunction-associated steatotic liver disease (MASLD). While e...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454815/ https://www.ncbi.nlm.nih.gov/pubmed/37628704 http://dx.doi.org/10.3390/genes14081653 |
_version_ | 1785096291440656384 |
---|---|
author | Petri, Belinda J. Cave, Matthew C. Klinge, Carolyn M. |
author_facet | Petri, Belinda J. Cave, Matthew C. Klinge, Carolyn M. |
author_sort | Petri, Belinda J. |
collection | PubMed |
description | Fatty liver disease is one of the major causes of morbidity and mortality worldwide. Fatty liver includes non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), now replaced by a consensus group as metabolic dysfunction-associated steatotic liver disease (MASLD). While excess nutrition and obesity are major contributors to fatty liver, the underlying mechanisms remain largely unknown and therapeutic interventions are limited. Reversible chemical modifications in RNA are newly recognized critical regulators controlling post-transcriptional gene expression. Among these modifications, N6-methyladenosine (m6A) is the most abundant and regulates transcript abundance in fatty liver disease. Modulation of m6A by readers, writers, and erasers (RWE) impacts mRNA processing, translation, nuclear export, localization, and degradation. While many studies focus on m6A RWE expression in human liver pathologies, limitations of technology and bioinformatic methods to detect m6A present challenges in understanding the epitranscriptomic mechanisms driving fatty liver disease progression. In this review, we summarize the RWE of m6A and current methods of detecting m6A in specific genes associated with fatty liver disease. |
format | Online Article Text |
id | pubmed-10454815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104548152023-08-26 Changes in m6A in Steatotic Liver Disease Petri, Belinda J. Cave, Matthew C. Klinge, Carolyn M. Genes (Basel) Review Fatty liver disease is one of the major causes of morbidity and mortality worldwide. Fatty liver includes non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), now replaced by a consensus group as metabolic dysfunction-associated steatotic liver disease (MASLD). While excess nutrition and obesity are major contributors to fatty liver, the underlying mechanisms remain largely unknown and therapeutic interventions are limited. Reversible chemical modifications in RNA are newly recognized critical regulators controlling post-transcriptional gene expression. Among these modifications, N6-methyladenosine (m6A) is the most abundant and regulates transcript abundance in fatty liver disease. Modulation of m6A by readers, writers, and erasers (RWE) impacts mRNA processing, translation, nuclear export, localization, and degradation. While many studies focus on m6A RWE expression in human liver pathologies, limitations of technology and bioinformatic methods to detect m6A present challenges in understanding the epitranscriptomic mechanisms driving fatty liver disease progression. In this review, we summarize the RWE of m6A and current methods of detecting m6A in specific genes associated with fatty liver disease. MDPI 2023-08-19 /pmc/articles/PMC10454815/ /pubmed/37628704 http://dx.doi.org/10.3390/genes14081653 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Petri, Belinda J. Cave, Matthew C. Klinge, Carolyn M. Changes in m6A in Steatotic Liver Disease |
title | Changes in m6A in Steatotic Liver Disease |
title_full | Changes in m6A in Steatotic Liver Disease |
title_fullStr | Changes in m6A in Steatotic Liver Disease |
title_full_unstemmed | Changes in m6A in Steatotic Liver Disease |
title_short | Changes in m6A in Steatotic Liver Disease |
title_sort | changes in m6a in steatotic liver disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454815/ https://www.ncbi.nlm.nih.gov/pubmed/37628704 http://dx.doi.org/10.3390/genes14081653 |
work_keys_str_mv | AT petribelindaj changesinm6ainsteatoticliverdisease AT cavematthewc changesinm6ainsteatoticliverdisease AT klingecarolynm changesinm6ainsteatoticliverdisease |